Bad-debt risk from deterioration in the financial condition of partner medical institutions
First written in FY2020-Q1. 5 of 17 entries say "Materialised", first in FY2020. Latest entry: FY2027-H1.
GLOME Holdings moved to the "Worse" side of this theme in 2023, 2 years before the typical company in this theme (2025).
0 other companies' latest entry also says "Mitigated".
- FY2027-H1MitigatedAnnual report
「Allowance for doubtful accounts (252) (135); Allowance for doubtful accounts (479) (464)」
The balance of the allowance for doubtful accounts, including current assets and investments and other assets, decreased from ¥731 million at the end of the previous fiscal year to ¥599 million. - FY2026MitigatedAnnual report
「Provision for allowance for doubtful accounts △ 34」
The provision for allowance for doubtful accounts for the consolidated fiscal year was a ¥34 million reversal, and the combined current and non-current allowance for doubtful accounts decreased from ¥771 million to ¥731 million. - 2026-05-28RestatedGeneral Meetings of Shareholders
「現状の貸倒引当金計上額で、発生する可能性のある損失を適切に見積っていると考えていますが、急激な経済金融情勢の変化が発生した場合、翌連結会計年度において実際の貸倒損失が引当金計上額と相違する可能性があります。」
貸倒引当金の個別評価、債権管理および経済金融情勢の変化による損失差異の可能性が、連結計算書類で再確認されている。 - FY2026-H1MitigatedAnnual report
「Provision for allowance for doubtful accounts 17 △ 4」
The provision for allowance for doubtful accounts included in selling, general and administrative expenses was reversed by ¥4 million in the interim period, compared with a ¥17 million provision in the same period of the previous year. - FY2025MaterialisedAnnual report
「Provision for allowance for doubtful accounts 111 17」
Following the recording of a ¥17 million provision for allowance for doubtful accounts during the interim consolidated accounting period, a provision for allowance for doubtful accounts was also recognized in FY2025. Credit risk in the healthcare-related and other businesses continues to be reflected in performance. - FY2025-H1MaterialisedAnnual report
「Provision for allowance for doubtful accounts 111 17」
During the interim consolidated accounting period, we recorded a ¥17 million provision for allowance for doubtful accounts in selling, general and administrative expenses. The balance of the allowance for doubtful accounts under current assets also increased from ¥288 million to ¥306 million. quantified is true, materialized is true. - FY2024WorsenedAnnual report
「The main factor behind the operating loss was the recording by our consolidated subsidiary GLOME Management Co., Ltd. of a ¥147 million provision for allowance for doubtful accounts in selling, general and administrative expenses.」
Regarding credit risk in the healthcare-related and other businesses, a ¥147 million provision for allowance for doubtful accounts was the main cause of the full-year operating loss. On the consolidated balance sheet, the allowance for doubtful accounts amounted to ¥288 million under current assets and ¥488 million under non-current assets. - FY2024-Q3WorsenedAnnual report
「The main factor behind the operating loss was the recording by our consolidated subsidiary GLOME Management Co., Ltd. of a ¥130 million provision for allowance for doubtful accounts in selling, general and administrative expenses.」
GLOME Management recorded a ¥130 million provision for allowance for doubtful accounts, making loss recognition associated with credit risk in the healthcare-related and other businesses the main cause of the operating loss. - FY2024-Q2WorsenedAnnual report
「The main factors were a ¥102 million decrease in long-term loans receivable due within one year and a ¥112 million increase in the allowance for doubtful accounts, offset by increases of ¥77 million in operating loans receivable and, following the consolidation of Fukuyama Medical Instruments Co., Ltd., ¥86 million in goodwill, ¥45 million in accounts receivable and ¥30 million in land.」
The allowance for doubtful accounts increased by ¥112 million, indicating expanded recognition of credit risk treatment relating to loans and receivables from partner medical institutions and other parties. - FY2024-Q1Increase in Allowance for Doubtful AccountsAnnual report
「The main factors were a ¥104 million increase in cash and deposits, offset by a ¥91 million decrease in long-term loans receivable due within one year and a ¥57 million increase in the allowance for doubtful accounts.」
The ¥57 million increase in the allowance for doubtful accounts was cited as a factor behind the decrease in total assets. - FY2022MitigatedAnnual report
「In the consolidated fiscal year ended March 2022, the impact of credit risk relating to loans and other receivables from alliance medical corporations was limited.」
It was explained that the impact of credit risk during the fiscal year was limited in relation to loans and other exposures to partner medical corporations. - FY2022-Q3MaterialisedAnnual report
「After reviewing the asset quality of medical corporations in relation to trade receivables from them, we recorded ¥24 million as a provision for allowance for doubtful accounts in selling, general and administrative expenses.」
The asset quality of medical corporations was reviewed in relation to trade receivables from them, and a ¥24 million provision for allowance for doubtful accounts was recorded. - FY2021MitigatedAnnual report
「We substantially revamped and strengthened our receivables management rules and introduced a stricter receivables and investment management framework.」
In response to bad-debt risk arising from deterioration in the financial condition of medical corporations, receivables and investment controls have been strengthened, and receivables collection and collateral preservation measures are being implemented. - FY2021-Q3MaterialisedAnnual report
「Beginning in the first quarter, we substantially overhauled our receivables management rules and have implemented stricter receivables management. For the cumulative year-to-date period, we recorded a net provision for allowance for doubtful accounts of ¥26 million in selling, general and administrative expenses.」
A ¥26 million provision for allowance for doubtful accounts related to receivables from partners and other parties was actually recorded on a cumulative year-to-date basis. - FY2020MaterialisedAnnual report
「As we recorded a provision for allowance for doubtful accounts of ¥424 million against trade receivables from medical corporations, the operating loss was ¥421 million, compared with operating income of ¥105 million in the same period of the previous year.」
A ¥424 million provision for allowance for doubtful accounts was actually recorded against trade receivables from partner medical corporations, and credit risk was reflected in performance. - FY2020-Q2RestatedAnnual report
「Some of the medical institutions with which we have business alliances purchase medical supplies and other products from us, and our group provides financing to some of them. However, deterioration in the financial condition of medical institutions with which we do business and other factors may give rise to potential bad-debt risk.」
Bad-debt risk arising from the deterioration in the financial condition of medical institutions in connection with sales and lending to partner medical institutions has been reiterated. - FY2020-Q1First statedAnnual report
「Some of the medical institutions with which we have business alliances purchase medical supplies and other products from us, and our group provides financing to some of them. However, deterioration in the financial condition of medical institutions with which we do business and other factors may give rise to potential bad-debt risk.」
Bad-debt risk arising from the deterioration in the financial condition of medical institutions in connection with medical-supplies sales and lending to partner medical institutions was disclosed for the first time.